RAD140 - CAS 1182367-47-0
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
RAD140
Catalog Number:
B0084-457306
Synonyms:
2-Chloro-4-[[(1R,2S)-1-[5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl]-2-hydroxypropyl]amino]-3-methylbenzonitrile;RAD 140
CAS Number:
1182367-47-0
Description:
RAD140, an effective non-steroidal selective androgen receptor modulator, could probably stimulate the increasing of muscle and also has been found to have potential neuroprotective properties in hippocampal neurons. It was just planed a trial for Breast
Molecular Weight:
393.83
Molecular Formula:
C20H16ClN5O2
Quantity:
Grams-Kilos
Quality Standard:
In-house Standard
COA:
Certificate of Analysis-RAD140 1182367-47-0 B16Q120401  
MSDS:
Inquire
Canonical SMILES:
CC1=C(C=CC(=C1Cl)C#N)NC(C2=NN=C(O2)C3=CC=C(C=C3)C#N)C(C)O
InChI:
1S/C20H16ClN5O2/c1-11-16(8-7-15(10-23)17(11)21)24-18(12(2)27)20-26-25-19(28-20)14-5-3-13(9-22)4-6-14/h3-8,12,18,24,27H,1-2H3/t12-,18+/m0/s1
InChIKey:
XMBUPPIEVAFYHO-KPZWWZAWSA-N
Targets:
Androgen Receptor
Current Developer:
Radius
Catalog Number Size Price Stock Quantity
B0084-457306 1 g $290 In stock
B0084-457306 50 g $1499 In stock
Bulk Inquiry
Chemical Structure
CAS 1182367-47-0 RAD140

Related Androgen Receptor Products


CAS 956104-40-8 ARN-509

ARN-509
(CAS: 956104-40-8)

ARN-509, also known as JNJ-56021927, is an androgen receptor antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby p...

CAS 154992-24-2 RU 58841

RU 58841
(CAS: 154992-24-2)

RU 58841 is a new non-steroidal antiandrogen which has potential for use in treating androgen-dependent skin disorders such as acne, hirsutism and androgen-depe...

ODM-201
(CAS: 1297538-32-9)

ODM-201 is a new-generation, potent and selective androgen receptor (AR) inhibitor which is potential useful for treatment of castration-resistant prostate canc...

CAS 90357-06-5 Bicalutamide

Bicalutamide
(CAS: 90357-06-5)

Bicalutamide is a non-steroidal androgen receptor (AR) antagonist with IC50 of 0.16 μM.

CAS 1242137-16-1 N-Desmethyl Enzalutamide

N-Desmethyl Enzalutamide
(CAS: 1242137-16-1)

N-desmethyl Enzalutamide is a major metabolite of Enzalutamide. Enzalutamide is an androgen-receptor (AR) antagonist (IC50 = 36 nM) in LNCaP cells that inhibits...

ASC-J9
(CAS: 52328-98-0)

ASC-J9 is an AR degradation enhancer, suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen rece...

CAS 1240299-33-5 AZD-3514

AZD-3514
(CAS: 1240299-33-5)

AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity. AZD3514 is being evaluated in a Phase I clinical trial in patie...

CAS 643094-49-9 Fasobegron

Fasobegron
(CAS: 643094-49-9)

Fasobegron acts a β3-adrenoreceptor agonist.

CAS 606101-58-0 MK-0773

MK-0773
(CAS: 606101-58-0)

MK-0773 is a selective androgen receptor modulator for the prevention and treatment of muscle wasting associated with cancer. It designed to improve muscle func...

MK-3984
(CAS: 871325-55-2)

MK-3984 is a androgen receptor modulators. It can be used for the prevention and treatment of muscle wasting associated with cancer.

JNJ-26146900
(CAS: 868691-50-3)

JNJ-26146900 is a selective, nonsteroidal androgen receptor modulator with tissue-selective activity in rats. It can bind to the rat AR with a Ki of 400nM and a...

MI-136
(CAS: 1628316-74-4)

MI-136, with the potential to treat refractory prostate cancer, inhibits DHT-induced expression of androgen receptor (AR) target genes. In vitro: Treatment with...

GLPG0492 R enantiomer
(CAS: 1215085-93-0)

The R-enantiomer of GLPG0492 which is a selective androgen receptor modulator, could be effective in decreasing muscle loss.

GSK-2881078
(CAS: 1539314-06-1)

GSK-2881078, an indole derivative, has been found to be an androgen receptor modulator that could probably be effective against Cachexia. It is still under Phas...

CAS 3546-41-6 Pyrvinium pamoate

Pyrvinium pamoate
(CAS: 3546-41-6)

Pyrvinium pamoate, a nonabsorbed anthelmintic drug, is a potent androgen receptor inhibitor and a selective WNT pathway inhibitor. Pyrvinium pamoate is a potent...

CAS 19608-29-8 Cortexolone 17 alpha-propionate

Cortexolone 17 alpha-propionate
(CAS: 19608-29-8)

Cortexolone 17 alpha-propionate, also called as CB-03-01, belonging to the family of ester derivatives of cortexolone, is a potent and topical and peripherally ...

CAS 401900-40-1 Andarine

Andarine
(CAS: 401900-40-1)

Andarine is a selective non-steroidal androgen receptor (AR) agonist with Ki of 4 nM, tissue-selective for anabolic organs.

CAS 915087-33-1 Enzalutamide

Enzalutamide
(CAS: 915087-33-1)

Enzalutamide is an androgen-receptor (AR) antagonist with IC50 of 36 nM. It inhibits the activity of prostate cancer cell Ars, which over expressed in prostate ...

CAS 427-51-0 Cyproterone acetate

Cyproterone acetate
(CAS: 427-51-0)

Cyproterone acetate is a synthetic derivative of 17-hydroxyprogesterone, and acts as an androgen receptor antagonist as well as a weak progesterone receptor ago...

ORM-15341
(CAS: 1297537-33-7)

ORM-15341, an androgen receptor antagonist, could have potential effect against prostate cancer and commonly found as an active main metabolite of ODM-201. IC50...

Reference Reading


1.Translational Highlights
HORM CANC (2014) 5:113–123
The decline in testosterone levels in men during normal aging increases risks of dysfunction and disease in androgenresponsive tissues, including brain. The use of testosterone therapy has the potential to increase the risks for developing prostate cancer and or accelerating its progression. To overcome this limitation, novel compounds termed selective androgen receptor modulators (SARMs) have been developed that lack significant androgen action in prostate but exert agonist effects in select androgen-responsive tissues. The efficacy of SARMs in brain is largely unknown. In this study, we investigate the SARM RAD140 in cultured rat neurons and male rat brain for its ability to provide neuroprotection, an important neural action of endogenous androgens that is relevant to neural health and resilience to neurodegenerative diseases. In cultured hippocampal neurons, RAD140 was as effective as testosterone in reducing cell death induced by apoptotic insults. Mechanistically, RAD140 neuroprotection was dependent upon MAPK signaling, as evidenced by elevation of ERK phosphorylation and inhibition of protection by the MEK inhibitor U0126. Importantly, RAD140 was also neuroprotective in vivo using the rat kainate lesion model. In experiments with gonadectomized, adult male rats, RAD140 was shown to exhibit peripheral tissue-specific androgen action that largely spared prostate, neural efficacy as demonstrated by activation of androgenic gene regulation effects, and neuroprotection of hippocampal neurons against cell death caused by systemic administration of the excitotoxin kainate. These novel findings demonstrate initial preclinical efficacy of a SARM in neuroprotective actions relevant to Alzheimer’s disease and related neurodegenerative diseases. This article appears in Endocrinology.